20-F: VisionSys AI Inc. Shifts Focus to Brain-Computer Interface Technology

VisionSys AI Inc. (formerly TCTM Kids IT Education Inc.) has completed the divestiture of its education businesses and is now exclusively focused on the development and commercialization of brain-computer interface (BCI) technologies.

Summary

• VisionSys AI Inc. has completed the divestiture of its professional education business (Divestiture 2024) and its STEM education business (Disposition 2025).
• The company is now exclusively focused on the development and commercialization of brain-computer interface (BCI) technologies and related businesses.
• The BCI business is centered on core algorithms, software, and hardware systems for brain-computer interaction, with potential applications in healthcare, wellness, and rehabilitation.
• The company acquired core algorithms and related software/hardware systems for BCI in April 2025.
• In 2025, the company generated RMB 1,039 (US$149) in net revenues from its BCI business, with a cost of revenues of RMB 810 (US$116), resulting in a gross profit of RMB 229 (US$33) and a gross margin of 22.0%.
• Operating expenses increased significantly in 2025 to RMB 40.2 million (US$5.8 million) due to expenses related to the new BCI subsidiary and intangible asset amortization.
• The company incurred a net loss from continuing operations of RMB 40.0 million (US$5.7 million) in 2025, compared to a net loss of RMB 13.9 million in 2024.
• The company has 17 employees as of April 22, 2026, primarily in IT and general administration, supporting its BCI operations.
• The company has not declared or paid any dividends and intends to retain earnings for business development.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the significant increase in operating losses and the impairment of BCI software, despite the strategic shift to a promising technology sector. The early stage of the BCI business and the substantial risks involved temper any positive outlook.

Positives

• Successful divestiture of legacy education businesses, allowing for a strategic focus on the emerging BCI technology sector.
• Acquisition of core BCI algorithms and related software/hardware systems in April 2025, providing a foundation for the new business.
• Generated initial revenue of RMB 1,039 (US$149) in the BCI segment in 2025, with a positive gross margin of 22.0%.
• Secured significant financing through various offerings in 2025, including a registered direct offering of approximately $12.0 million in November 2025 and a registered direct offering of approximately $3.0 million in March 2026.
• The company's ADSs are listed on the Nasdaq Capital Market, providing access to public capital markets.

Negatives

• Significant increase in operating expenses in 2025 to RMB 40.2 million (US$5.8 million), leading to a net loss from continuing operations of RMB 40.0 million (US$5.7 million).
• The BCI business is in its early stages with limited operating history and revenue.
• The company has a history of net losses from continuing operations in 2023, 2024, and 2025.
• The company has limited insurance coverage for its BCI operations.
• The company faces significant risks related to the evolving BCI industry, including technological, regulatory, market acceptance, and competitive challenges.
• The company has experienced a change in auditors multiple times in a short period (Marcum Asia CPAs LLP, Guangdong Prouden CPAs GP, and Assentsure PAC).

Risks

• The BCI industry is highly competitive, and the company may be unable to compete with companies with greater financial or technical resources.
• The commercialization progress of BCI technologies may fall short of expectations, and market acceptance may be limited.
• Implementation challenges may arise due to the need to integrate complex software and hardware systems, potentially leading to prolonged development cycles.
• The company's ability to protect its intellectual property and trade secrets may be impaired, affecting its ability to compete.
• Cybersecurity risks and data protection laws in China pose significant challenges to the company's operations.
• The company's reliance on PRC subsidiaries for cash flow is subject to restrictions on dividend payments and capital transfers offshore.
• Changes in PRC government policies and regulations, particularly concerning technology and foreign investment, could adversely affect the company's business.
• The company's ADSs could be delisted from Nasdaq if it fails to meet continued listing requirements.
• The company may be classified as a Passive Foreign Investment Company (PFIC), leading to adverse U.S. federal income tax consequences for U.S. Holders.
• The company has identified impairment indicators for its BCI software due to R&D delays, regulatory challenges, and revenue shortfalls, resulting in an impairment loss of RMB 21.0 million in 2025.

Future Outlook

The company is focused on the development and commercialization of BCI technologies, aiming to generate revenue from technical services and product sales. The BCI business is in its early stages, and future success depends on technological advancements, regulatory approvals, market acceptance, and securing sufficient capital. The company intends to focus on non-invasive general wellness products in the short term, with a medium-term strategy to explore medical and rehabilitation applications, and a long-term strategy for broader BCI ecosystem development and international expansion.

Management Comments

• Our BCI business is still at an early stage, and the commercialization of BCI technologies remains subject to substantial uncertainty, including technological, regulatory, clinical, market acceptance, supply chain, intellectual property, capital, and execution risks.
• We intend to focus primarily on non-invasive BCI-related products and services with comparatively lower regulatory and technical barriers, including general wellness management, sleep support, attention monitoring, meditation devices, rehabilitation support products, EEG acquisition devices, and customized BCI-related technical services.
• In the short term, we intend to focus on non-invasive general wellness management products and services. These may include sleep support devices, attention monitoring headbands, meditation devices, stress relief devices, rehabilitation training devices, EEG acquisition devices, and other general wellness or BCI-adjacent products.
• In the medium term, we intend to explore medical and rehabilitation-related applications with more specific functional needs. These may include rehabilitation assistance, mobility support, functional recovery, brain state monitoring, assistive devices, and other healthcare-related solutions.

Industry Context

StockSavvy.ai notes that VisionSys AI Inc.'s strategic pivot to Brain-Computer Interface (BCI) technology aligns with a growing global interest in neurotechnology and its potential applications across healthcare, wellness, and human-computer interaction. The BCI market is characterized by rapid innovation and significant investment, but also faces substantial regulatory hurdles and a need for robust clinical validation, particularly for medical applications. The company's focus on non-invasive, general wellness applications in the near term is a prudent approach to navigate these complexities while building market presence.

Management Changes

Legal Proceedings

• A putative securities class action lawsuit (Yili Qiu v. Tarena International, Inc. et al.) was filed in June 2021, alleging false or misleading statements in SEC filings. A settlement received preliminary approval in September 2023 and final approval in September 2024. This matter relates to the company's legacy education business, which has been divested.

Related Party Transactions

• Disposal of controlling interest in Gaohuiqiangxue Software (Hainan) Co., Ltd. to a consortium including a former chairman's relative.
• Divestiture of professional education business to a buyer consortium including the sister of the former chairman.
• Transactions with Tarena Tech for shared HR and IT staff services.

Stakeholder Impact

• Shareholders may face difficulties in protecting their interests due to Cayman Islands incorporation and limited recourse through U.S. courts.
• Investors in ADSs may experience dilution if the company issues more shares.
• The company's dual-class share structure limits the voting influence of Class A shareholders.
• Potential delisting from Nasdaq could reduce ADS liquidity and market price.
• U.S. Holders of ADSs or Class A ordinary shares may face adverse U.S. federal income tax consequences if the company is classified as a Passive Foreign Investment Company (PFIC).

Next Steps

• Focus on developing and commercializing BCI technologies and related products/services.
• Explore non-invasive general wellness and rehabilitation support products in the short term.
• Potentially explore medical and rehabilitation applications in the medium term.
• Consider broader BCI ecosystem development and international expansion in the long term.
• Continue to recruit qualified personnel for BCI operations, including R&D and technical roles.

Key Dates

Recommendation

VisionSys AI Inc. has made a significant strategic shift to the BCI sector, which holds future potential but is currently in an early, high-risk stage. The company has divested its legacy businesses and is focusing on developing BCI technology, evidenced by the acquisition of core algorithms and initial revenue generation. However, the company continues to incur substantial operating losses, has impaired intangible assets, and faces significant execution and regulatory risks inherent in the BCI industry. While recent financing activities provide some liquidity, the path to profitability remains uncertain. Given the speculative nature of the BCI market and the company's current financial performance, a 'hold' recommendation is appropriate, with investors advised to closely monitor the company's progress in commercializing its BCI technology and managing its operational costs.

Keywords

VisionSys AI Inc, TCTM Kids IT Education Inc, Brain-Computer Interface, BCI, SEC Filing, Form 20-F, Annual Report, Technology, Healthcare, Rehabilitation, AI, Divestiture, Nasdaq